Phase 1/2 Study to Evaluate Safety and Immunogenicity of a Prophylactic Plasmid DNA Booster Vaccine Against SARS-CoV-2 (Covigenix VAX-002) in Generally Healthy Adults 18 Years and Older Covigenix VAX-002 was designed to address the new circulating omicron variants of SARS-CoV-2 Aegis Life, Inc. continues to support the vaccine trials as a global commercialization partner for […] Read The Rest at :
Disclaimer : Mymoneytimes implements extreme caution and care in collecting data before publication. Mymoneytimes does not liable for the adequacy, accuracy or completeness of any given information. Hence we are not liable for any kind of direct or indirect loss caused by the use of such information.
